Clinical Report: Risk-Adjusted Antithrombotic Strategies in NVUGIB

Overview

This study evaluates the impact of adherence to a risk-based antithrombotic management framework on 30-day clinical outcomes following endoscopic treatment for non-variceal upper gastrointestinal bleeding (NVUGIB).

Background

Non-variceal upper gastrointestinal bleeding (NVUGIB) is a critical medical emergency requiring prompt intervention, especially in patients on antithrombotic therapy. The management of NVUGIB is complicated by the need to balance the risks of rebleeding with thromboembolic complications. Current guidelines advocate for individualized risk assessments to optimize patient outcomes.

Data Highlights

Key Findings

• Adherence to the antithrombotic management framework was linked to lower rebleeding rates (adjusted OR 0.03).
• Adherence also correlated with a reduction in net adverse clinical events (NACE) (adjusted OR 0.04).
• Rebleeding occurred in 5.2% of adherent patients compared to 17.8% of non-adherent patients.
• NACE was observed in 12.0% of adherent patients versus 34.0% of non-adherent patients.
• Overall, 9.2% of patients experienced rebleeding within 30 days post-treatment.
• Timing of antithrombotic resumption was critical, with 7 rebleeding events occurring on or before the recorded resumption date.

Clinical Implications

The findings suggest that adherence to a structured, risk-based antithrombotic management framework can significantly reduce adverse outcomes in patients undergoing endoscopic treatment for NVUGIB. Clinicians should prioritize individualized assessments of thromboembolic risk when planning antithrombotic therapy resumption.

Conclusion

The study highlights the importance of adherence to a risk-based management framework in reducing adverse clinical outcomes following endoscopic treatment for NVUGIB. Individualized assessments are crucial for optimizing patient care.

Related Resources & Content

1. Surgical Endoscopy, 2024 -- Identifying Risk Factors for Rebleeding and Mortality After Prophylactic Transarterial Embolization in High-Risk Peptic Ulcer Bleeding: A Retrospective Cohort Analysis from a Single Center
2. Journal of Gastroenterology, 2024 -- Choosing the Most Effective Direct Oral Anticoagulant for Endoscopic Submucosal Dissection in the Upper Gastrointestinal Tract
3. Surgical Endoscopy, 2022 -- Comparison of Mortality Rates: Over-the-Scope Clips (OTSC) Versus Surgical Intervention for Persistent Peptic Ulcer Bleeding in a Retrospective Analysis
4. BMJ Open Gastroenterology, 2023 -- Development and internal validation of the AGATE hybrid score for pre-endoscopic risk stratification in acute upper gastrointestinal bleeding: a single-centre, retrospective cohort study
5. Endoscopic diagnosis and management of peptic ulcer bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2026 - PubMed
6. Timing of Antiplatelet and Anticoagulant Therapy Resumption Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis - Clinical Gastroenterology and Hepatology
7. AJG-21-2066 1..17 -- ACG-CAG Guideline
8. 2026 ESGE Guideline for Peptic Ulcer Bleeding
9. Timing of Antiplatelet and Anticoagulant Therapy Resumption Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis - Clinical Gastroenterology and Hepatology
10. AJG-21-2066 1..17